Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8356503 | 0.91 | MAPK1 (0.51) | TDP1APPALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL304176 | 0.86 | TDP1 (0.78) | TDP1APPALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL28207503 | 0.84 | TDP1 (0.75) | TDP1APPALDH1A1MAPK1L3MBTL1 | |
| Bicarbonate SCHEMBL7699565 | 0.84 | TDP1 (0.75) | TDP1APPALDH1A1MAPK1L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL28588274 | 0.84 | TDP1 (0.75) | TDP1APPALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL197805 | 0.84 | APP (0.76) | TDP1APPALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL5450328 | 0.84 | TDP1 (0.56) | TDP1APPALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL22276673 | 0.84 | TDP1 (0.56) | TDP1APPALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2745464 | 0.84 | CYP4F2 (0.57) | TDP1APPALDH1A1TYRDRD2 | |
| SCHEMBL56760 | 0.83 | ALDH1A1 (0.73) | TDP1ALDH1A1MAPK1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240043470-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | UNIV CORNELL (US) | 2024-02-08 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220324907-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2022-10-13 | — | — | US | disclosed |
| EP-3694508-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | Cornell University (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019075259-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
| CN-101336246-B | Phosphonic acid diester derivative and method for producing same | PING ZHURUN | 2012-11-28 | — | — | CN | disclosed |
| US-8129557-B2 | Phosphonic acid diester derivative and method for producing thereof | Nagai, Kazuhiro (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | HIRATAKE, GOU (JP) | 2009-06-25 | — | — | US | disclosed |
| CN-101336246-A | Phosphonic acid diester derivative and method for producing same | HIRATAKE JUN (JP) | 2008-12-31 | — | — | CN | disclosed |
| EP-0339549-A2 | Tyr-peptide analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043470-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB3 | TDP1 2070/4885APP 1967/4885ALDH1A1 4081/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | TDP1 2070/4885APP 1967/4885ALDH1A1 4081/4885 |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | PPA1, G6PD, PHOSPHO1 | TDP1 1759/4885APP 2330/4885ALDH1A1 1716/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | TDP1 2070/4885APP 1967/4885ALDH1A1 4081/4885 |
| US-20220324907-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB3 | TDP1 2070/4885APP 1967/4885ALDH1A1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.